Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Apr;32(4):650-7.
doi: 10.2337/dc08-1863. Epub 2008 Dec 29.

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

James F List  1 , Vincent Woo, Enrique Morales, Weihua Tang, Fred T Fiedorek
Affiliations
Randomized Controlled Trial

Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes

James F List et al. Diabetes Care. 2009 Apr.

Abstract

Objective: Dapagliflozin, a novel inhibitor of renal sodium-glucose cotransporter 2, allows an insulin-independent approach to improve type 2 diabetes hyperglycemia. In this multiple-dose study we evaluated the safety and efficacy of dapagliflozin in type 2 diabetic patients.

Research design and methods: Type 2 diabetic patients were randomly assigned to one of five dapagliflozin doses, metformin XR, or placebo for 12 weeks. The primary objective was to compare mean change from baseline in A1C. Other objectives included comparison of changes in fasting plasma glucose (FPG), weight, adverse events, and laboratory measurements.

Results: After 12 weeks, dapagliflozin induced moderate glucosuria (52-85 g urinary glucose/day) and demonstrated significant glycemic improvements versus placebo (DeltaA1C -0.55 to -0.90% and DeltaFPG -16 to -31 mg/dl). Weight loss change versus placebo was -1.3 to -2.0 kg. There was no change in renal function. Serum uric acid decreased, serum magnesium increased, serum phosphate increased at higher doses, and dose-related 24-h urine volume and hematocrit increased, all of small magnitude. Treatment-emergent adverse events were similar across all groups.

Conclusions: Dapagliflozin improved hyperglycemia and facilitates weight loss in type 2 diabetic patients by inducing controlled glucosuria with urinary loss of approximately 200-300 kcal/day. Dapagliflozin treatment demonstrated no persistent, clinically significant osmolarity, volume, or renal status changes.

Trial registration: ClinicalTrials.gov NCT00263276.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Patient disposition and study design. T2DM, type 2 diabetic.
Figure 2
Figure 2
Changes in glycemic parameters. A: Adjusted mean change from baseline in A1C at week 12 (LOCF). B: Mean change in FPG over time (observed values). C: Adjusted mean change from baseline in postprandial glucose area under the curve (AUC) during a 75-g oral glucose tolerance test at week 12 (LOCF). D: Change from baseline in 24-h urinary glucose (grams) normalized for urinary creatinine (grams) at week 12 (LOCF). Displayed are means and 95% CIs (A, B, and D). When statistical significance was achieved with dapagliflozin groups compared with placebo, Dunnett's multiplicity adjustment was used. P values versus placebo at week 12.
Figure 3
Figure 3
Percent changes in weight. A: Percent change from baseline in weight over the 12-week treatment period and 4-week follow-up period (observed values). B: Adjusted mean percent change from baseline in weight after 12 weeks of treatment (LOCF). Displayed are means and 95% CIs.
See this image and copyright information in PMC

References

    1. Kles KA, Vinik AI: Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. Curr Diabetes Rev 2: 131– 145, 2006 - PubMed
    1. Nazimek-Siewniak B, Moczulski D, Grzeszczak W: Risk of macrovascular and microvascular complications in type 2 diabetes: results of longitudinal study design. J Diabetes Complications 16: 271– 276, 2002 - PubMed
    1. Rahman S, Rahman T, Ismail AA, Rashid AR: Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab 9: 767– 780, 2007 - PubMed
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577– 1589, 2008 - PubMed
    1. Andrews WJ, Vasquez B, Nagulesparan M, Klimes I, Foley J, Unger R, Reaven GM: Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes 33: 634– 642, 1984 - PubMed

Publication types

MeSH terms

Associated data